Literature DB >> 12738448

Losses of heterozygosity on chromosomes 9p and 17p are frequent events in Barrett's metaplasia not associated with dysplasia or adenocarcinoma.

Alexandra Suspiro1, A Dias Pereira, Ana Afonso, Cristina Albuquerque, Paula Chaves, Jorge Soares, C Nobre Leitão.   

Abstract

OBJECTIVE: Losses of heterozygosity (LOH) on chromosomes 9p and 17p frequently accompany malignant transformation of Barrett's esophagus (BE). They have been reported in adenocarcinoma, dysplasia, and adjacent metaplasia of patients with long-segment BE (LSBE). This study aimed to evaluate and compare the frequency of LOH on 9p and 17p in patients with long- and short-segment BE (SSBE) without dysplasia or adenocarcinoma.
METHODS: Matched metaplasia and blood DNA were evaluated for LOH on chromosomes 9p and 17p in patients with a previous diagnosis of BE and no dysplasia or cancer.
RESULTS: We included 18 patients (12 long-segment BE and six short-segment BE). The overall prevalence of LOH was 61% (10 of 18), with no significant difference between LSBE (58%) and SSBE (50%). The frequencies of LOH on 9p and 17p were similar (35% and 39%, respectively), with 18% of the patients showing losses at both chromosomes.
CONCLUSIONS: LOH on 9p and 17p are highly frequent events in BE, even in the absence of dysplasia and adenocarcinoma. The presence of these abnormalities in non-neoplastic epithelium suggests they might be useful markers for risk stratification within endoscopic surveillance programs.

Entities:  

Mesh:

Year:  2003        PMID: 12738448     DOI: 10.1111/j.1572-0241.2003.07411.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  4 in total

Review 1.  From genetics to signaling pathways: molecular pathogenesis of esophageal adenocarcinoma.

Authors:  Ravindran Caspa Gokulan; Monica T Garcia-Buitrago; Alexander I Zaika
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2019-05-30       Impact factor: 10.680

Review 2.  Treatment for Barrett's oesophagus.

Authors:  Jonathan Re Rees; Pierre Lao-Sirieix; Angela Wong; Rebecca C Fitzgerald
Journal:  Cochrane Database Syst Rev       Date:  2010-01-20

3.  NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma.

Authors:  Patricia C Galipeau; Xiaohong Li; Patricia L Blount; Carlo C Maley; Carissa A Sanchez; Robert D Odze; Kamran Ayub; Peter S Rabinovitch; Thomas L Vaughan; Brian J Reid
Journal:  PLoS Med       Date:  2007-02       Impact factor: 11.069

4.  Loss of heterozygosity at thymidylate synthase locus in Barrett's metaplasia, dysplasia, and carcinoma sequences.

Authors:  Hidekazu Kuramochi; Kazumi Uchida; Jeffery H Peters; Daisuke Shimizu; Daniel Vallbohmer; Sylke Schneider; Kathleen D Danenberg; Peter V Danenberg
Journal:  BMC Cancer       Date:  2009-05-21       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.